These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25703027)

  • 1. Variations of ITSS-Morphology and their Relationship to Location and Tumor Volume in Patients with Glioblastoma.
    Fahrendorf D; Hesselmann V; Schwindt W; Wölfer J; Jeibmann A; Kooijman H; Kugel H; Heindel W; Bink A
    J Neuroimaging; 2015; 25(6):1015-22. PubMed ID: 25703027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility-Weighted Imaging of Glioma: Update on Current Imaging Status and Future Directions.
    Hsu CC; Watkins TW; Kwan GN; Haacke EM
    J Neuroimaging; 2016 Jul; 26(4):383-90. PubMed ID: 27227542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive assessment of intratumoral vascularity using arterial spin labeling: A comparison to susceptibility-weighted imaging for the differentiation of primary cerebral lymphoma and glioblastoma.
    Furtner J; Schöpf V; Preusser M; Asenbaum U; Woitek R; Wöhrer A; Hainfellner JA; Wolfsberger S; Prayer D
    Eur J Radiol; 2014 May; 83(5):806-10. PubMed ID: 24613549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme.
    Fahrendorf D; Schwindt W; Wölfer J; Jeibmann A; Kooijman H; Kugel H; Grauer O; Heindel W; Hesselmann V; Bink A
    Eur Radiol; 2013 Oct; 23(10):2868-79. PubMed ID: 23903995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging.
    Radbruch A; Wiestler B; Kramp L; Lutz K; Bäumer P; Weiler M; Roethke M; Sahm F; Schlemmer HP; Wick W; Heiland S; Bendszus M
    Eur J Radiol; 2013 Mar; 82(3):552-6. PubMed ID: 23238364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging.
    Park MJ; Kim HS; Jahng GH; Ryu CW; Park SM; Kim SY
    AJNR Am J Neuroradiol; 2009 Aug; 30(7):1402-8. PubMed ID: 19369602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of postcontrast susceptibility-weighted imaging in the assessment of intracranial brain neoplasm at 3T.
    Kang H; Jang S
    Acta Radiol; 2021 Jun; 62(6):791-798. PubMed ID: 32664747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
    Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
    Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
    Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading.
    Su CQ; Lu SS; Han QY; Zhou MD; Hong XN
    Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative vs. semiquantitative assessment of intratumoral susceptibility signals in patients with different grades of glioma.
    Bhattacharjee R; Gupta RK; Patir R; Vaishya S; Ahlawat S; Singh A
    J Magn Reson Imaging; 2020 Jan; 51(1):225-233. PubMed ID: 31087724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High intratumoral susceptibility signal grade on susceptibility-weighted imaging: a risk factor for hemorrhage after stereotactic biopsy.
    Tanji M; Mineharu Y; Sakata A; Okuchi S; Fushimi Y; Oishi M; Terada Y; Sano N; Yamao Y; Arakawa Y; Yoshida K; Miyamoto S
    J Neurosurg; 2023 Jan; 138(1):120-127. PubMed ID: 35561695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastomas vs. lymphomas: more diagnostic certainty by using susceptibility-weighted imaging (SWI).
    Peters S; Knöß N; Wodarg F; Cnyrim C; Jansen O
    Rofo; 2012 Aug; 184(8):713-8. PubMed ID: 22618484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast medium enhanced susceptibility imaging signal mechanism; should we use contrast medium?
    Aydın Ö; Büyükkaya R; Hakyemez B
    Acta Radiol; 2017 Jan; 58(1):107-113. PubMed ID: 26966145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-parametric effect in predicting tumor histological grade by using susceptibility weighted magnetic resonance imaging in tongue squamous cell carcinoma.
    Yang X; Zhu J; Dai Y; Tian Z; Yang G; Shi H; Wu Y; Tao X
    BMC Med Imaging; 2019 Mar; 19(1):24. PubMed ID: 30866854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3Tesla.
    Radbruch A; Graf M; Kramp L; Wiestler B; Floca R; Bäumer P; Roethke M; Stieltjes B; Schlemmer HP; Heiland S; Bendszus M
    Eur J Radiol; 2012 Dec; 81(12):4064-8. PubMed ID: 22795527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.
    Liberman G; Louzoun Y; Aizenstein O; Blumenthal DT; Bokstein F; Palmon M; Corn BW; Ben Bashat D
    Eur J Radiol; 2013 Feb; 82(2):e87-94. PubMed ID: 23017192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.